当前蛋白身份：Q13557
重新检索
差异标签只比较当前检索结果；所有PDB和assembly原始记录仍分别保留。
相关结构差异明细
一行代表一个 PDB 条目中的一个 biological assembly；同一蛋白的多个单体会分别列出。
| PDB 条目 | Assembly / 聚集状态 | 构建体 | 突变与修饰 | 配体、离子与非聚合物 | 实验方法 | 实验环境 | 结构质量 |
|---|---|---|---|---|---|---|---|
| 2VN9 Crystal Structure of Human Calcium Calmodulin dependent Protein Kinase II delta isoform 1, CAMKD 提交 2008-01-31 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
11–309（299 aa）
片段：KINASE DOMAIN, RESIDUES 11-309
|
未记录 | PO4 PHOSPHATE ION × 2 CL CHLORIDE ION × 1 EPE 4-(2-HYDROXYETHYL)-1-PIPERAZINE ETHANESULFONIC ACID × 1 GVD [4-({4-[(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)AMINO]QUINAZOLIN-2-YL}IMINO)CYCLOHEXA-2,5-DIEN-1-YL]ACETONITRILE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
pH 7.5；1.6 M NAKPO4 HEPES PH 7.5
|
分辨率 2.30 Å R-free 0.248 |
| 2VN9 Crystal Structure of Human Calcium Calmodulin dependent Protein Kinase II delta isoform 1, CAMKD 提交 2008-01-31 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
11–309（299 aa）
片段：KINASE DOMAIN, RESIDUES 11-309
|
未记录 | PO4 PHOSPHATE ION × 2 GVD [4-({4-[(5-CYCLOPROPYL-1H-PYRAZOL-3-YL)AMINO]QUINAZOLIN-2-YL}IMINO)CYCLOHEXA-2,5-DIEN-1-YL]ACETONITRILE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
pH 7.5；1.6 M NAKPO4 HEPES PH 7.5
|
分辨率 2.30 Å R-free 0.248 |
| 2W2C STRUCTURE OF THE TETRADECAMERIC OLIGOMERISATION DOMAIN OF CALCIUM- CALMODULIN DEPENDENT PROTEIN KINASE II DELTA 提交 2008-10-28 | Assembly 1 蛋白同源多聚体 同源多聚体；蛋白 × 14 PDB 声明：tetradecameric（14） 与蛋白数一致 |
链 A
334–475（142 aa）
片段：OLIGOMERISATION DOMAIN, RESIDUES 334-475
链 B
334–475（142 aa）
片段：OLIGOMERISATION DOMAIN, RESIDUES 334-475
链 C
334–475（142 aa）
片段：OLIGOMERISATION DOMAIN, RESIDUES 334-475
链 D
334–475（142 aa）
片段：OLIGOMERISATION DOMAIN, RESIDUES 334-475
链 E
334–475（142 aa）
片段：OLIGOMERISATION DOMAIN, RESIDUES 334-475
链 F
334–475（142 aa）
片段：OLIGOMERISATION DOMAIN, RESIDUES 334-475
链 G
334–475（142 aa）
片段：OLIGOMERISATION DOMAIN, RESIDUES 334-475
链 H
334–475（142 aa）
片段：OLIGOMERISATION DOMAIN, RESIDUES 334-475
链 I
334–475（142 aa）
片段：OLIGOMERISATION DOMAIN, RESIDUES 334-475
链 J
334–475（142 aa）
片段：OLIGOMERISATION DOMAIN, RESIDUES 334-475
链 K
334–475（142 aa）
片段：OLIGOMERISATION DOMAIN, RESIDUES 334-475
链 L
334–475（142 aa）
片段：OLIGOMERISATION DOMAIN, RESIDUES 334-475
链 M
334–475（142 aa）
片段：OLIGOMERISATION DOMAIN, RESIDUES 334-475
链 N
334–475（142 aa）
片段：OLIGOMERISATION DOMAIN, RESIDUES 334-475
|
未记录 | ACT ACETATE ION × 14 CD CADMIUM ION × 6 | X-RAY DIFFRACTION |
X-ray结晶条件
pH 4.6；30% PEG400, 0.1M CADMIUM CHLORIDE, 0.1M SODIUM ACETATE PH4.6
|
分辨率 2.70 Å R-free 0.245 |
| 2WEL Crystal structure of SU6656-bound calcium/calmodulin-dependent protein kinase II delta in complex with calmodulin 提交 2009-03-31 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 A
11–335（325 aa）
片段：KINASE DOMAIN, RESIDUES 11-335
|
未记录 | K88 (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE × 1 EDO 1,2-ETHANEDIOL × 6 PO4 PHOSPHATE ION × 2 CA CALCIUM ION × 4 | X-RAY DIFFRACTION |
X-ray结晶条件
pH 7.5；0.1M SODIUM POTASSIUM PHOSPHATE, 20% PEG3350 10% ETHYLENE GLYCOL, pH 7.5
|
分辨率 1.90 Å R-free 0.199 |
| 3GP2 Calmodulin bound to peptide from calmodulin kinase II (CaMKII) 提交 2009-03-20 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 4 PDB 声明：tetrameric（4） 与蛋白数一致 |
链 B
294–311（18 aa）
片段：residues 294-311
|
非标准单体：是（mmCIF未提供具体位点） | CA CALCIUM ION × 8 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；0.1 M sodium acetate pH 4.6, 0.2 M ammonium acetate, 30% PEG 4000, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
分辨率 1.46 Å R-free 0.192 |
| 3GP2 Calmodulin bound to peptide from calmodulin kinase II (CaMKII) 提交 2009-03-20 | Assembly 2 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 B
294–311（18 aa）
片段：residues 294-311
|
非标准单体：是（mmCIF未提供具体位点） | CA CALCIUM ION × 4 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 4.6；298 K；0.1 M sodium acetate pH 4.6, 0.2 M ammonium acetate, 30% PEG 4000, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
分辨率 1.46 Å R-free 0.192 |
| 5VLO The structure of human CamKII with bound inhibitor 提交 2017-04-25 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
3–301（299 aa）
片段：UNP residues 3-301
|
未记录 | 9EJ N-[(2S)-2-(diethylamino)propyl]-2-[(2S)-2-(methylcarbamoyl)azetidin-1-yl]-6-[5-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl]pyridine-4-carboxamide × 1 DTT 2,3-DIHYDROXY-1,4-DITHIOBUTANE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；293 K；CamKII S3-K301, in 20mM imidazole pH 8.5, 0.3M sodium chloride, 5mM TCEP, was concentrated to 36 mg/ml and flash frozen in liquid nitrogen for long term storage at -80 C in 10 uL aliquots. The protein was thawed and diluted down to 12 mg/mL in the same buffer just prior to crystallization experiments. Sitting drop vapor diffusion droplets were assembled with 250 nL of 12 mg/mL CamKII, 0.6 mM inhibitor and 250 nL of reservoir solution 24% peg 3350, 0.2 M ammonium tartrate, 0.1 M arginine. Flat crystal plates (typically 0.03 mm x 0.2 mm x 0.4 mm in size) grew in 4-7 days at 20 C. A crystal seed suspension was prepared with ten crushed crystals combined into 100 uL of reservoir solution and stored at -80 C. A thirty fold seed dilution was prepared in the same solution for addition to protein droplets in a 1 to 1 volume ratio to enhance crystallization of difficult to crystallize inhibitors.
|
分辨率 2.05 Å R-free 0.226 |
| 5VLO The structure of human CamKII with bound inhibitor 提交 2017-04-25 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
3–301（299 aa）
片段：UNP residues 3-301
|
未记录 | 9EJ N-[(2S)-2-(diethylamino)propyl]-2-[(2S)-2-(methylcarbamoyl)azetidin-1-yl]-6-[5-(thiophen-2-yl)pyrazolo[1,5-a]pyrimidin-3-yl]pyridine-4-carboxamide × 1 DTT 2,3-DIHYDROXY-1,4-DITHIOBUTANE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；293 K；CamKII S3-K301, in 20mM imidazole pH 8.5, 0.3M sodium chloride, 5mM TCEP, was concentrated to 36 mg/ml and flash frozen in liquid nitrogen for long term storage at -80 C in 10 uL aliquots. The protein was thawed and diluted down to 12 mg/mL in the same buffer just prior to crystallization experiments. Sitting drop vapor diffusion droplets were assembled with 250 nL of 12 mg/mL CamKII, 0.6 mM inhibitor and 250 nL of reservoir solution 24% peg 3350, 0.2 M ammonium tartrate, 0.1 M arginine. Flat crystal plates (typically 0.03 mm x 0.2 mm x 0.4 mm in size) grew in 4-7 days at 20 C. A crystal seed suspension was prepared with ten crushed crystals combined into 100 uL of reservoir solution and stored at -80 C. A thirty fold seed dilution was prepared in the same solution for addition to protein droplets in a 1 to 1 volume ratio to enhance crystallization of difficult to crystallize inhibitors.
|
分辨率 2.05 Å R-free 0.226 |
| 6AYW The structure of human CamKII with bound inhibitor 提交 2017-09-08 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
3–301（299 aa）
片段：UNP residues 3-301
|
未记录 | C2V N-[2-(dimethylamino)ethyl]-3-[6-(thiophen-2-yl)imidazo[1,2-b]pyridazin-3-yl]benzamide × 1 DTT 2,3-DIHYDROXY-1,4-DITHIOBUTANE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；293 K；CamKII S3-K301, in 20mM imidazole pH 8.5, 0.3M sodium chloride, 5mM TCEP, was concentrated to 36 mg/ml and flash frozen in liquid nitrogen for long term storage at -80 C in 10 microL aliquots. The protein was thawed and diluted down to 12 mg/mL in the same buffer just prior to crystallization experiments. Sitting drop vapor diffusion droplets were assembled with 250 nL of 12 mg/mL CamKII, 0.6 mM inhibitor and 250 nL of reservoir solution 24% peg 3350, 0.2 M ammonium tartrate, 0.1 M arginine. Flat crystal plates (typically 0.03 mm x 0.2 mm x 0.4 mm in size) grew in 4-7 days at 20 C. A crystal seed suspension was prepared with ten crushed crystals combined into 100 uL of reservoir solution and stored at -80 C. A thirty fold seed dilution was prepared in the same solution for addition to protein droplets in a 1 to 1 volume ratio to enhance crystallization of difficult to crystallize inhibitors.
|
分辨率 2.05 Å R-free 0.267 |
| 6AYW The structure of human CamKII with bound inhibitor 提交 2017-09-08 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
3–301（299 aa）
片段：UNP residues 3-301
|
未记录 | C2V N-[2-(dimethylamino)ethyl]-3-[6-(thiophen-2-yl)imidazo[1,2-b]pyridazin-3-yl]benzamide × 1 DTT 2,3-DIHYDROXY-1,4-DITHIOBUTANE × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；293 K；CamKII S3-K301, in 20mM imidazole pH 8.5, 0.3M sodium chloride, 5mM TCEP, was concentrated to 36 mg/ml and flash frozen in liquid nitrogen for long term storage at -80 C in 10 microL aliquots. The protein was thawed and diluted down to 12 mg/mL in the same buffer just prior to crystallization experiments. Sitting drop vapor diffusion droplets were assembled with 250 nL of 12 mg/mL CamKII, 0.6 mM inhibitor and 250 nL of reservoir solution 24% peg 3350, 0.2 M ammonium tartrate, 0.1 M arginine. Flat crystal plates (typically 0.03 mm x 0.2 mm x 0.4 mm in size) grew in 4-7 days at 20 C. A crystal seed suspension was prepared with ten crushed crystals combined into 100 uL of reservoir solution and stored at -80 C. A thirty fold seed dilution was prepared in the same solution for addition to protein droplets in a 1 to 1 volume ratio to enhance crystallization of difficult to crystallize inhibitors.
|
分辨率 2.05 Å R-free 0.267 |
| 7ZRP 2.65 Angstrom crystal structure of Ca/CaM:CaMKIIdelta peptide complex 提交 2022-05-04 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 B
294–315（22 aa）
|
未记录 | CA CALCIUM ION × 4 PG4 TETRAETHYLENE GLYCOL × 2 IMD IMIDAZOLE × 1 ZN ZINC ION × 5 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；292 K；200 mM Zinc acetate, 100 mM Imidazole pH8.0, 18% PEG3000
|
分辨率 2.65 Å R-free 0.272 |
| 7ZRP 2.65 Angstrom crystal structure of Ca/CaM:CaMKIIdelta peptide complex 提交 2022-05-04 | Assembly 2 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 D
294–315（22 aa）
|
未记录 | CA CALCIUM ION × 4 IMD IMIDAZOLE × 1 ZN ZINC ION × 4 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；292 K；200 mM Zinc acetate, 100 mM Imidazole pH8.0, 18% PEG3000
|
分辨率 2.65 Å R-free 0.272 |
| 7ZRQ 1.68 Angstrom crystal structure of Ca/CaM-E140G:CaMKIIdelta peptide complex 提交 2022-05-04 | Assembly 1 蛋白异源复合物 异源复合物；蛋白 × 2 PDB 声明：dimeric（2） 与蛋白数一致 |
链 B
294–315（22 aa）
|
未记录 | CA CALCIUM ION × 4 GOL GLYCEROL × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, HANGING DROP；292 K；0.1 M Na+-HEPES, 0.1 M MOPS (acid), pH 7.5, 0.03 M magnesium chloride hexahydrate, 0.03 M calcium chloride dihydrate, 12.5% v/v MPD; 12.5% PEG 1000; 12.5% w/v PEG 3350
|
分辨率 1.68 Å R-free 0.244 |
| 9BLH Crystal structure of calcium/calmodulin-dependent protein kinase type II subunit delta complexed with ribociclib 提交 2024-04-30 | Assembly 1 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 A
10–309（300 aa）
|
未记录 | 6ZZ 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.2 M CaCl2, 0.15 M NaCl, 12% (w/v) PEG 3350, 0.7 mM ribociclib and 35% (w/v) ethylene glycol
|
分辨率 2.35 Å R-free 0.251 |
| 9BLH Crystal structure of calcium/calmodulin-dependent protein kinase type II subunit delta complexed with ribociclib 提交 2024-04-30 | Assembly 2 蛋白单体 单体；蛋白 × 1 PDB 声明：monomeric（1） 与蛋白数一致 |
链 B
10–309（300 aa）
|
未记录 | 6ZZ 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide × 1 | X-RAY DIFFRACTION |
X-ray结晶条件
VAPOR DIFFUSION, SITTING DROP；pH 8；293 K；0.2 M CaCl2, 0.15 M NaCl, 12% (w/v) PEG 3350, 0.7 mM ribociclib and 35% (w/v) ethylene glycol
|
分辨率 2.35 Å R-free 0.251 |